The direct answer

Bimagrumab is an antibody directed at activin type II receptors. It is studied in the broader myostatin/activin pathway, but it is not a short peptide or a selective label for every myostatin-related intervention.[1][2]

Class
Receptor-targeting antibody
Research focus
Body composition
Reading priority
Separate fat, lean mass & weight

What does bimagrumab target?

Its receptor-targeting strategy differs from an antibody that binds myostatin itself. The point of intervention matters because several signals can use related receptor pathways.[1]

Think of the question as “Where is the interruption?” rather than simply “Does it inhibit myostatin?” A compound profile should identify its target before describing a result. The comparison guide places bimagrumab alongside other approaches.

Which human studies are relevant?

A 2021 randomized study examined body composition in adults with type 2 diabetes and overweight or obesity. The later BELIEVE trial tested bimagrumab, semaglutide, and combinations in adults with obesity. These are clinical research settings, not studies of recreational peptide products.[1][2]

The two studies asked related but different questions. A single-agent comparison should not be merged with a combination regimen, and a population with diabetes should not silently become “everyone.”

Which numbers should you look for?

Read fat mass, lean mass, and total body weight as separate outcomes. They use different denominators and describe different parts of body composition. A percentage reduction in fat mass cannot be rewritten as the same percentage reduction in body weight.

Strength and daily function also need their own measurements. A body-composition scan does not by itself establish that a participant can lift more, walk farther, or live more independently.

An outcome is not interchangeable with its neighbor
MeasureQuestion it can help answer
Fat massHow much measured fat changed
Lean massHow measured non-fat soft tissue changed
Body weightHow total scale weight changed
FunctionHow performance on a defined task changed

How should the evidence be described?

The 2026 BELIEVE publication describes bimagrumab as investigational.[2] Its study findings should be read with the full design, adverse-event report, and publication date. This profile does not turn that research into a prescribing recommendation.

For the original results and their denominators, read the 2021 body-composition summary and the BELIEVE trial guide.

Questions, answered.

Is bimagrumab the same kind of treatment as apitegromab?

Both are antibodies, but they act at different targets. Bimagrumab targets receptors; apitegromab targets myostatin proforms.

Can a lean-mass increase be called a strength increase?

Only if strength was actually measured and the relevant result supports that statement. Lean mass and strength are different outcomes.

Sources & further reading

Primary research and official records used for this page. Study results apply to the populations and interventions described.

  1. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityHeymsfield et al. · JAMA Network Open · 2021 · Phase 2 randomized trial
  2. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trialHeymsfield et al. · Nature Medicine · 2026 · BELIEVE trial
Educational information, not individualized medical advice. This article has not been independently reviewed by a clinician. Regulatory and research details are dated; check the linked primary records for subsequent changes.